Preoperative Evaluation & Perioperative Risk Optimization

Comprehensive preoperative assessment and risk-modification for colorectal surgery patients: cardiac/pulmonary risk, medication management, diabetes/obesity/malnutrition, transplant recipients, substance abuse, immunosuppressive/biologic/chemotherapy agents and anastomotic healing, and elderly/ frailty assessment with prehabilitation. Synthesized from ASCRS Ch. 6 — a general perioperative- medicine chapter, the first in this ingest not primarily anatomy/physiology/technique-focused. Textbook reference content, not primary literature. Elective abdominal colorectal surgery sits in the intermediate cardiac-risk category (1–5% 30-day MI/death rate); perforated viscus is high risk (>5%).

Routine evaluation and testing

History/physical should reconcile medications (including anticoagulants/OTC/herbal), assess bleeding history, and estimate exercise capacity (walking up a flight of stairs / brisk walk to the exam table ≈ ≥4 METs — a validated surrogate for perioperative cardiac risk and for frailty). Anorectal surgery generally needs minimal workup in healthy patients.

Routine "shotgun" preoperative labs have low yield in asymptomatic patients (a landmark 2,000-patient retrospective study found only 0.2% of non-indicated tests changed management). Selective testing: hemoglobin for all patients ≥65 or with anemia risk; type and screen for all major abdominal surgery (bowel resection); creatinine for patients ≥50 (independent predictor of cardiac complications and mortality); electrolytes/glucose/LFTs/urinalysis only if history-indicated; pregnancy testing for all women of childbearing age. ECG per ACC/AHA guidelines for known heart disease, peripheral arterial disease, or cerebrovascular disease — not routinely for asymptomatic low-risk patients. CXR for known cardiopulmonary disease, age ≥50 undergoing major abdominal surgery, or BMI ≥40 — otherwise low yield. Advanced imaging: MR enterography is valuable in Crohn's disease (see Crohn Disease) to distinguish active inflammatory from chronic fibrotic disease (the former more medically responsive, the latter often needing surgery) and has supplanted fluoroscopic small-bowel follow-through; pelvic MRI is now standard for rectal cancer locoregional staging (see Rectal Cancer); CT chest/abdomen/pelvis for colon/rectal cancer distant metastatic workup and operative planning (en-bloc resection needs, adjacent-organ involvement) and for diverticulitis (abscess/fistula/adjacent inflammation evaluation, see Diverticulitis).

Cardiac evaluation

Most common postoperative cardiac events: MI, heart failure, arrhythmia, cardiac arrest. Clinical risk factors: angina, prior MI, heart failure, stroke/TIA, renal impairment, insulin-dependent diabetes. Functional capacity (METs) is central to the decision algorithm: ≥4 METs → proceed to surgery regardless of other risk factors; <4 METs or unknown → further cardiac evaluation/risk-benefit analysis (only if it would actually change management — routine coronary revascularization purely to reduce noncardiac perioperative risk is not supported by evidence). A 12,846-patient study found significantly lower postoperative complications/mortality in colorectal cancer patients with preoperative MET ≥12 vs. <12 (12.1% vs 14.9% complications, p=0.006), plus improved disease-free and overall survival.

Risk indices: the Revised Goldman Cardiac Risk Index (RCRI) scores MI-within-6-months, age >70, S3/JVD, significant AS, non-sinus rhythm or PVCs on ECG, poor general medical status, intraperitoneal/ intrathoracic/aortic surgery, and emergency surgery — mapping to four risk classes with cardiac-death probability ranging 0.2% (class I) to 56% (class IV). The ACS-NSQIP risk calculator is a more input-heavy, procedure-specific alternative. Patients with >1% estimated perioperative cardiac-death risk should be evaluated by cardiology; further testing (echocardiography, stress testing, 24-hour monitoring, catheterization) is reserved for patients whose results would actually change management.

Medical optimization: continue longstanding beta-blockers, but never initiate de novo preoperatively (multiple studies/meta-analyses link new perioperative beta-blockade to increased nonfatal stroke and MI risk when started <24h before surgery). Target BP 116–130 mmHg systolic, 60–70 bpm to avoid perioperative hypotension. Decompensated heart failure risk can be mitigated with ≥1 week preoperative ACE inhibitor/aldosterone antagonist/digoxin. Continue statins already prescribed; preoperative statin initiation is reasonable before vascular surgery specifically, with no data supporting preemptive initiation for colorectal surgery.

Preoperative anticoagulation

Two broad categories relevant to nonvalvular atrial fibrillation: vitamin K antagonists (warfarin — still the most widely used) and direct oral anticoagulants (DOACs: apixaban, dabigatran, edoxaban, rivaroxaban — factor Xa inhibitors with rapid onset 1–3h, generally no bridging needed, no routine monitoring). DOACs carry an FDA boxed warning for spinal/epidural hematoma with neuraxial anesthesia and should not be routinely used perioperatively if epidural/spinal anesthesia is planned.

Warfarin: interruption timing depends on INR (3–4 days prior for INR 1.5–1.9, 5 days for INR 2.0–3.0, ≥5 days for INR >3.0); most abdominal procedures are safe at INR <1.4; reversal for urgent/life-threatening bleeding uses vitamin K (oral/IV) or FFP for emergencies.

DOACs: interruption duration based on estimated half-life (4–5 half-lives) and procedural bleeding risk — typically stop 3 days prior / resume 2–3 days postop for high-risk procedures, stop 2 days prior / resume 1 day postop for low-risk procedures. Reversal agents: idarucizumab for dabigatran (2 doses of 2.5g IV ≤15 min apart); andexanet alfa (AndexXa) for apixaban/edoxaban/rivaroxaban.

Coronary stents: continue dual antiplatelet therapy (DAPT — aspirin + clopidogrel/prasugrel/ ticagrelor) for ≥12 months; stent thrombosis risk is highest in the first 4–6 weeks after either bare-metal or drug-eluting stent placement, and DAPT discontinuation in this early window is a strong thrombosis risk factor. Nonemergent noncardiac surgery: wait ≥30 days after bare-metal stents; continue anticoagulation >6 months after drug-eluting stents (3–6 months acceptable on individual case review). Continue low-dose aspirin through the interruption when holding DAPT; resume P2Y12 inhibitors ASAP postop. For emergent abdominal surgery within 3 months of drug-eluting stent placement, IV short-acting antiplatelet bridging (e.g., tirofiban, started ≤24h preop, discontinued 4h preop, restarted 2h postop until clopidogrel resumption) can be considered — requires close surgeon/cardiologist/anesthesiologist coordination.

Bridging: generally a VKA-specific concept (DOACs typically don't need it). Bridge only if significant thrombotic risk (CHA₂DS₂-VASc ≥7–9, or ischemic stroke/TIA/systemic embolism within 3 months) and acceptable bleeding risk — assessed via the HAS-BLED score (hypertension, abnormal renal/hepatic function, prior stroke, major-bleed history, labile INR, age >65, concomitant antiplatelet/NSAID use, alcohol/drug use; score ≥3 = "high risk"). Restart VKA within 24h post-procedure (bridging heparin 24–72h depending on bleed risk); resume DOACs at full dose the day after low-bleed-risk procedures, or wait ≥48–72h after high-bleed-risk procedures.

Prosthetic valves: mechanical valves need lifelong warfarin anticoagulation (more durable, fewer reoperations, but more bleeding complications than bioprosthetic); bioprosthetic valves need anticoagulation for only 3 months (aspirin ± clopidogrel may substitute after TAVR). Elective noncardiac surgery should be avoided in the first few months post-valve-replacement if possible; mechanical aortic valve + any thromboembolism risk generally warrants LMWH bridging (held 5 days preop, restarted 24h postop as bleeding allows).

AICD/pacemakers: identify pacemaker-dependence preoperatively with cardiology; pacemaker-dependent patients may need intraoperative reprogramming. All AICD patients need an external defibrillator and transcutaneous pacer immediately available; a magnet placed over the device prevents inappropriate shock delivery during monopolar cautery (which causes electromagnetic interference) — bipolar/ ultrasonic energy preferred when feasible to reduce this risk.

Pulmonary assessment

Postoperative pulmonary complications (atelectasis, pneumonia/bronchitis, hypoxemia, COPD/asthma exacerbation, respiratory failure) occur in 2–70% of cases across the literature (one NSQIP-based study: 6% in 165,196 major-abdominal-surgery patients; a more recent 7-institution prospective study found ≥1 complication in 33.4%, with significantly increased mortality/ICU utilization). Routine pulmonary function tests are NOT indicated for healthy patients — clinical findings (decreased breath sounds, prolonged expiratory phase, rales, rhonchi, wheezes) are more predictive than spirometry; PFTs reserved for unexplained dyspnea or high-risk factors. COPD is the single most important pulmonary-complication risk factor (up to 25% of elderly COPD patients have an operative pulmonary complication, mortality approaching 7%). Other patient risk factors: advanced age, ASA ≥2, functional dependence, elevated Goldman index, CHF (notably, obesity is not an independent pulmonary-complication risk factor). Procedure-related risks: aortic aneurysm repair, non-resective thoracic surgery, abdominal surgery, neurosurgery, emergency surgery, general anesthesia, head/neck surgery, vascular surgery, prolonged surgery.

Smoking cessation: encourage cessation — the older belief that cessation <8 weeks preop paradoxically worsens pulmonary complications (via compensatory increased secretions) has been disproven in multiple large studies; a 522-patient trial found postoperative pulmonary complication ORs of 2.92 (active smokers/quit <2wk), 0.98 (quit 4–8wk), 1.42 (quit ≥8wk) vs. never-smokers — recommendation is to encourage cessation regardless of surgical timing, ideally ≥4 weeks out.

Obstructive sleep apnea (OSA): one of the most common sleep disorders, a risk factor for perioperative cardiopulmonary complications and unplanned ICU admission; screen patients undergoing major abdominal surgery similarly to high-BMI/multi-comorbidity patients (e.g., STOP-Bang questionnaire, with high-scorers referred for pulmonology workup).

Perioperative steroid management

Colorectal surgeons frequently encounter chronic steroid therapy (IBD, rheumatologic disease, transplant — see Crohn Disease, Ulcerative Colitis). Chronic steroid use risks secondary adrenal insufficiency/HPA-axis suppression, manifesting perioperatively as adrenal crisis (altered mental status, abdominal pain, nausea/vomiting, weakness, hypotension). Prednisone 20mg/day for

3 weeks is the most commonly cited threshold for HPA suppression risk; exact recovery timeline is individual, but suppression generally doesn't persist beyond 1 year post-cessation. Chronic glucocorticoids also carry surgery-relevant adverse effects independent of HPA suppression: impaired wound healing, skin/vessel/tissue atrophy, fracture risk, GI hemorrhage/ulcer, and increased infection risk including anastomotic leak (see Immunosuppressive agents below).

Dosing protocols stratify by anticipated surgical stress (minor/moderate/major) and HPA-suppression risk category (low/high, by steroid dose/duration or Cushingoid features) — a colon resection is "moderate" stress, warranting daily home dose plus hydrocortisone 50–75mg IV with a 1–2 day taper if the patient is in the high-suppression-risk category. However, recent data challenge the necessity of routine stress-dose steroids: a 2012 retrospective IBD-surgery cohort found low-dose perioperative steroids (equivalent to home dose) sufficient without vasopressor need for hemodynamic instability, and a subsequent RCT found no difference in postural hypotension/adrenal insufficiency between high-dose (hydrocortisone 100mg IV TID) and low-dose glucocorticoid regimens in major colorectal surgery — stress-dose steroids may carry minimal benefit over continuing the patient's usual preoperative dose, with rescue-dose steroids reserved for refractory perioperative hypotension. Hydrocortisone is the preferred agent for acute stress/rescue coverage given its mineralocorticoid activity.

Diabetes

Complex subset given long-term complications (neuropathy, visual impairment, peripheral/mesenteric vascular disease) and comorbidities (chronic renal insufficiency, cardiovascular disease). Preop workup for major abdominal surgery: ECG, CXR, creatinine, glucose, and HbA1c within 4–6 weeks (elevated A1c independently associated with increased surgical-complication risk in cardiac surgery literature, extrapolated here). Many centers postpone elective surgery for HbA1c >6.5 given cardiac complication and septic-sequelae rates, until improved glycemic control is achieved. Anesthesiology coordination is critical (some patients need preop IV insulin infusion for euglycemia, plus intraoperative insulin); all diabetic patients maintained on a postoperative sliding-scale regimen plus home medications; perioperative hyperglycemia risks wound infection and anastomotic dehiscence. Enhanced Recovery After Surgery (ERAS) (ASCRS Ch7) adds a specific HbA1c-based preop triage algorithm (normal/prediabetic/diabetic pathways, goal perioperative blood sugar <150 mg/dL) within its ERAS-protocol framing — complementary detail, not restated here.

Obesity

1/3 of US adults are obese (BMI ≥30); 1/20 are super-obese (BMI ≥40). Obesity is a screening tool, not a direct malnutrition-exclusion criterion (see Malnutrition below — obesity and malnutrition coexist more often than assumed, via sarcopenic obesity). Risks: increased VTE and superficial SSI (one 6,000+ patient study: 4% vs 3% SSI, obese vs. nonobese, p=0.03); NSQIP-derived studies show incremental SSI odds with increasing obesity class, plus increased wound disruption, sepsis, respiratory/renal complications, UTI; increased thromboembolism and superficial SSI rates and inability to create tension-free pouches/anastomoses to the lower rectum/anus in obese patients (relevant to Ileal Pouch-Anal Anastomosis (IPAA), which already notes obesity/tall stature/long torso complicate tension-free reach — this chapter adds that obesity independently increases anastomotic/pouch-anal leak rate, not just technical reach difficulty). Increased operative time is consistently seen. Practical mitigations: laparoscopic approach where feasible (smaller incisions, less pain, better visualization), avoiding lower-midline/Pfannenstiel incisions in patients with a large pannus, stoma-site marking by an enterostomal therapist preoperatively (thinner upper abdomen is often the better site, and patients need to physically reach their stoma), ensuring OR availability of long instruments/deep retractors/appropriate beds/large pneumatic compression boots. Preoperative weight loss (very-low-calorie diets, pharmacotherapy, or even bariatric/metabolic surgery) has been advocated by many, aiming to shrink mesenteric/visceral adiposity, liver size, and pelvic fat pads for better exposure — notably, in malignancy, increasing time-to-surgery for this optimization has not been shown to worsen disease-specific survival.

Malnutrition

Distinct from (and can coexist with) obesity. Colorectal surgeons commonly see malnutrition from advanced malignancy or IBD (intestinal blockage/fistula/poor absorption/large-volume GI losses). Nutritional risk correlates with worse postoperative complications, longer stay, higher mortality — particularly pronounced in colorectal cancer. Evaluation: history (intolerance of oral intake, weight loss over 1–3 months) and exam (thin, pale, weak, muscle wasting, loose skin); graded via tools like the Subjective Global Assessment (SGA) (5 history features + 4 exam features → well-nourished/moderately/severely malnourished classification). Serum albumin <4.0 g/dL has been the "classic" marker of malnutrition; some groups now propose adding hypoalbuminemia (<4/dL) as a negative-prognostic risk factor to the ACS-NSQIP surgical risk calculator, though its reliability is limited by non-nutritional causes of fluctuation (catabolic/anabolic state, external losses, fluid redistribution) — the chapter explicitly flags this as an unresolved methodological limitation, not a settled recommendation. Similar limitations apply to prealbumin/transferrin/retinol-binding protein.

Sarcopenia — muscle wasting, distinct from but often co-occurring with malnutrition — is increasingly assessed via CT/MRI psoas cross-sectional area at L3, normalized for height. A 350-patient study found ~1/3 of colorectal-cancer-surgery patients sarcopenic, with significantly longer length of stay (13 vs 7 days), higher 1-year mortality (13.9% vs 0.9%), and higher any/major complication rates — all p<0.01. Preoperative identification enables prehabilitation targeting nutrition and exercise (see below).

Nutritional intervention: options include oral supplements, nasoenteric tube feeding, or TPN (1.5g protein/kg + 25 kcal/kg, tight glycemic control <150 mg/dL) if enteral access isn't feasible. Evidence quality is limited (a Cochrane review found only 2 enteral-nutrition trials, both small/ high-bias, showing no outcome difference; 3 older parenteral-nutrition trials showed reduced postoperative complications specifically in malnourished patients) — the chapter is candid that preoperative nutrition support in this population remains understudied relative to its clinical importance.

Solid organ transplant recipients

150,000 US patients live with functional kidney transplants (a rising number), so colorectal surgeons increasingly encounter transplant patients on chronic immunosuppression, continued perioperatively to minimize rejection risk. mTOR inhibitors (sirolimus, everolimus) specifically impair wound healing by inhibiting lymphocyte proliferation via the same mTOR-kinase mechanism that underlies their immunosuppressive effect — an RCT of 123 kidney-transplant patients found significantly higher wound-related complications (SSI, incisional hernia) with sirolimus vs. tacrolimus (47% vs 8%, p<0.0001), prompting a common practice of switching mTOR-inhibitor patients to tacrolimus for ~6 weeks before elective surgery. Nonoperative management may be preferable when possible in chronically immunosuppressed patients. Transplant patients requiring emergency surgery are more likely to need stoma creation (with lower restoration-of-continuity rates) and have increased mortality vs. non-transplant immunosuppressed patients — historically, immunocompromised diverticulitis patients were recommended early elective resection after a single episode, but this is "no longer the case" per this chapter and should be individualized (see Diverticulitis cross-reference below).

Substance abuse

~7.6% of Americans had a substance-use disorder in the prior year per one large database study — the chapter emphasizes universal, nonjudgmental screening ("never safe to assume a patient doesn't fit the profile").

Alcohol: dose-dependent association with SSI/other infections, cardiopulmonary complications, longer stay, higher ICU/reoperation rates. AUDIT-C is a validated screening tool. An RCT of 41 alcoholic patients (>60g ethanol/day) undergoing elective colorectal surgery found 1-month preoperative abstinence significantly reduced cardiac complications (23% vs 85%) and arrhythmias (33% vs 86%); optimal abstinence duration is unknown, but investigators recommend 3–8 weeks of intensive counseling/monitoring.
Tobacco: increases pulmonary risk, wound infection, neurologic complications, ICU admission — see Pulmonary Assessment above for the revised cessation-timing guidance (encourage cessation regardless of timing, ideally ≥4 weeks preop).
Opioids: chronic opioid dependence (illicit, prescription-misuse, or legitimately prescribed for chronic pain) increases perioperative narcotic requirements regardless of underlying indication. Always ask preoperatively about indication, duration, side effects (e.g., constipation), any weaning plan, and prescriber — corroborate with the prescribing physician/ record. Multimodal non-narcotic adjuncts (thoracic epidural, TAP blocks, ketorolac, acetaminophen, gabapentin) are recommended; a clear postoperative pain-management plan should be established preoperatively with the prescribing clinician to avoid outpatient overprescribing/ relapse risk.
Other illicit drugs: screen for all substances (not just "street drugs" — also non-medically- indicated prescription-only drugs like benzodiazepines); encourage cessation before elective surgery with primary-care/psychiatric coordination.

Immunosuppressive agents, biologics, and chemotherapy: anastomotic healing risk

The chapter's own framing: "the current literature is quite conflicting and controversial" on this topic — presented here largely as-is, not resolved, consistent with this wiki's practice of flagging genuine unresolved tension rather than picking a side.

Corticosteroids impair wound healing in animal models across all three healing phases (inflammatory, proliferative, remodeling). Clinical anastomotic-leak data: a 1980s prospective Crohn's study found steroids associated with higher postoperative complication rate (15.4% vs 6.7%, p=0.03); a 250-patient left-colon-resection study found corticosteroid use increased AL risk more than sevenfold (OR 7.52, p=0.001); a meta-analysis of 9,564 patients across 12 studies found overall leak rates of 6.77% (corticosteroid-exposed) vs 3.26% (non-exposed); in UC specifically, doses

4mg/day led to a statistically significant complication increase; the CD-specific TREAT registry found a smaller but still significant infectious-complication increase (OR 2.21). A more recent meta-analysis specifically on corticosteroids and IPAA complications found equivocal results — not uniformly confirmatory.

Biologic agents (infliximab, adalimumab, certolizumab — anti-TNF; ustekinumab — anti-IL-12/23; natalizumab/vedolizumab — anti-integrin/adhesion; tofacitinib — JAK inhibitor) are more targeted in mechanism than steroids but paradoxically can still inhibit the pathways needed for anastomotic wound healing. Individual study findings, genuinely mixed:

A 518-patient IBD study found no difference in anastomotic leak with preoperative infliximab (2.1% vs 1.3%, p=0.81) despite the infliximab group having significantly more concurrent steroid use (73.9% vs 58.8%, p=0.006) — steroid co-exposure didn't worsen the null result here.
A meta-analysis by Wong found a consistent ~20% increase in infectious complications with anti-TNF in Crohn's disease (OR 1.5), despite significant heterogeneity across included trials. Ileal-pouch-anal-anastomosis studies with anti-TNF exposure were split on effect; other institutional data found OR 3.5 for infectious complications broadly (anastomotic leak p=0.02, pouch-specific complications p=0.01, other infections p<0.01, sepsis p=0.001). Vedolizumab specifically increased postoperative complications more than anti-TNF agents or no treatment in one series, and independently predicted 30-day postoperative SSI when used within 12 weeks of surgery.
A 3,860-patient NSQIP colectomy-for-Crohn's-disease study found immunosuppression independently increased infectious complications (OR 1.25), overall SSI (OR 1.40), organ-space SSI (OR 1.47), and anastomotic leak (OR 1.41) on multivariate analysis.
Most recently and most rigorously (per the chapter's framing): the PUCCINI trial — a prospective, multi-institution study designed specifically to answer this question — found preoperative anti-TNF use (whether by history or drug level) was not an independent risk factor for postoperative infection, including SSI (p=0.92 for TNF use within 12 weeks; p=0.513 for any detectable level), with no difference by steroid use or other immunosuppressant use either.

Practical synthesis (the chapter's own bottom line, reflecting current high-volume-IBD-center practice more than a single definitive trial): most surgeons still prefer to hold biologics for the equivalent of ~3.5 half-lives (6–8 weeks for most anti-TNF agents, 12 weeks for vedolizumab) before major surgery when elective; steroids should be weaned to ≤20mg prednisone daily, sustained ≥2 weeks preoperatively; a temporarily diverting stoma should be considered when these medical optimizations aren't achievable preoperatively.

Chemotherapy: cytotoxic chemotherapy's mechanism (inducing cell death in rapidly proliferating cells) can theoretically affect healing anastomoses, though again the literature conflicts. A 797-patient single-center study found preoperative chemotherapy one of the strongest independent anastomotic-leak risk factors (OR 2.85, p=0.017); a similarly sized 682-patient 5-year study found chemotherapy (within 6 weeks of surgery) was not a risk factor for leak in bivariate analysis. A 131-patient diverticulitis-in-chemotherapy-patients series found chemotherapy patients more likely to need emergent surgery, diversion, and postoperative complications after interval resection, plus significantly worse overall survival — but recurrent diverticulitis itself was not more common or more complicated in this group, and nonoperative management of acute episodes remained safe/effective (directly extends Diverticulitis's existing immunocompromised-patient content — see cross-reference below).

Bevacizumab (VEGF-A inhibitor, antiangiogenic) is specifically associated with increased postoperative complications including impaired wound healing and anastomotic leak — phase II/III studies now exclude patients who had major surgery within the prior 28 days as a result. A 78-patient retrospective study of resectable advanced/metastatic colorectal cancer patients who received neoadjuvant bevacizumab found a median 9-week interval from last dose to surgery, with anastomotic leaks in 6 patients (4 needing re-laparotomy) — this corroborates and quantifies Total Neoadjuvant Therapy (TNT)'s existing brief mention of bevacizumab's fistula/healing-problem risk. Current recommendation: hold antiangiogenic agents (bevacizumab and others implicated, including pazopanib and aflibercept in smaller series) for ≥6 weeks before major surgery, with careful consideration of anastomosis and/or proximal diversion. Newer checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) have limited colorectal-specific surgical safety data, though extrapolated data from bladder/lung surgery suggests acceptable (if nontrivial) morbidity.

Preoperative assessment in the elderly

Chronologic age alone is a poor surrogate for the functional/physical/cognitive decline that actually drives perioperative risk — most US colorectal surgery patients are now >65, making this population assessment central rather than a special case.

Frailty has no single consensus definition; the two dominant models are phenotypic frailty (physical activity, muscle strength, energy level — Fried's 2001 five-domain criteria: unintentional weight loss ≥10lb/year, decreased grip strength, exhaustion, low physical activity, slowed walking speed; ≥3 domains = frail) and deficit-accumulation frailty (nutrition, cognition, medical conditions, functional decline).

See Geriatric Considerations in Colorectal Surgery for a dedicated deep-dive on this population (ASCRS Ch. 67) — additional geriatric-oncology-specific screening tools (fTRST, G8, TUG-vs-ASA comparison), functional-recovery/PROM framework, and a rectal-cancer-specific treatment algorithm not covered here.

Comprehensive geriatric assessment (CGA) is the gold-standard multidimensional tool (comorbidity, functional status, physical performance, cognition, psychological status, nutrition, medication review, social support). Predicts prolongation of life, prevention of hospitalization/ adult-living-facility admission, prevention of delirium/falls, prevention of cognitive decline, and detection of unsuspected conditions affecting cancer treatment in >50% of patients ≥70. Multiple studies (a 178-patient Norwegian colorectal-cancer cohort; a 201-patient study using 7 frailty characteristics) independently confirm frailty predicts postoperative complications, prolonged stay, and 30-day readmission — a 2015 systematic review of 6 CGA studies in geriatric oncology found deficiencies in instrumental/basic ADLs, fatigue, cognition, frailty, and cognitive impairment all associated with increased postoperative complications (though not, interestingly, with mortality directly); a separate 980-patient study found each additional CGA-deficit domain associated with a 40% increase in 6-month postoperative mortality risk, while ASA classification was not independently associated with 6-month mortality in the same cohort — a notable finding given ASA's ubiquity as a risk-stratification tool.

Shorter alternatives to full CGA (which can take hours): the Hopkins Frailty Score (Makary 2010, adapting Fried's criteria — prospectively validated in 594 patients, frailty independently associated with postoperative complications OR 2.54, length of stay OR 1.69, discharge to a non-home facility OR 20.48); the modified frailty index (mFI) (11 NSQIP-derived variables, each worth one point — predicts 30-day readmission, major complications, wound complications, failure to enhance recovery protocol adherence, discharge to non-home facility, and mortality); the risk analysis index (RAI) (14-question survey of ADLs/cognitive decline plus standard factors — predicts prolonged stay, non-ICU discharge to nursing home, mortality). The American College of Surgeons/ American Geriatrics Society jointly recommend a preoperative checklist covering cognitive impairment, frailty, polypharmacy, malnutrition risk, and social support — though translating this into reliably predictive clinical outcomes has remained challenging in practice.

Cognitive dysfunction and delirium: cognitive dysfunction (dementia to mild cognitive impairment, MCI) affects 5–15% of the general elderly population, up to 60% in high-risk surgical groups, and independently worsens surgical outcomes. Screening tools: Mini-Cog (3-minute, ACS/AGS-endorsed — 3-item recall + clock-drawing test) and SAGE (12-item self-administered). Delirium is one of the most common postoperative complications in the elderly — one prospective study of abdominal surgery patients >70 found 60% overall incidence, with 20% 30-day mortality among those who developed delirium, and 40% of delirium patients had 3–4 identifiable risk factors preoperatively. Six modifiable risk factors (visual/hearing impairment, cognitive impairment, sleep deprivation, immobility, dehydration) respond to non-pharmacologic management (avoidance of triggers, reorientation, massage, relaxing music, one-on-one family care) as first-line therapy; medication (preferentially haloperidol) is reserved for severe cases, avoiding restraints where possible.

Prehabilitation

Multidisciplinary, multimodal (exercise, nutrition, psychosocial) preoperative intervention aimed at optimizing functional/physiologic/psychological reserve before surgical stress, to prevent or diminish surgery-related functional decline. No standardized consensus definition yet exists; reported intervention duration ranges 5 days to 6 weeks across settings (home, rehab center, outpatient/inpatient physiotherapy).

Exercise: the dominant component across programs — aerobic, resistance, and flexibility training combined for comprehensive functional improvement; most programs show improved physical performance post-intervention.
Nutrition: malnourishment affects 2–32% of elderly (even in "healthy" geriatric populations), with a sixfold increased complication risk in malnourished elderly patients, amplified further in the setting of GI cancer. Screening tools (SGA, Mini Nutritional Assessment) identify candidates for individualized multimodal nutritional therapy (energy requirements, high protein diet, balanced macronutrients).
Psychosocial therapy: preoperative anxiety/depression negatively affect quality of life, wound healing, infection rates, length of stay, and treatment adherence — interventions include educational sessions, relaxation techniques, and guided imagery.

Outcomes evidence is genuinely mixed — the chapter is candid that prehabilitation's theoretical benefit for high-risk (elderly) patients lacks consistent supporting evidence. One study (Waite et al.) found a significant 30% reduction in overall complications and 20% reduction in severe complications, with the only significant mortality/length-of-stay benefit seen across the reviewed literature. Most other studies show no difference in mortality or length of stay; a randomized trial by Carli et al. specifically in frail colorectal cancer surgery patients (mean age 78, ~80% minimally invasive) found no difference in the primary outcome (30-day Comprehensive Complications Index) or secondary outcomes (complications, length of stay, ED visits/readmissions, recovery of walking capacity, patient-reported outcomes) between prehabilitation and rehabilitation. A more recent 2020 systematic review of 5,921 patients (35 studies; only 45 studies total compared prehab vs. no-prehab directly, 26 abdominal/19 cardiothoracic) found major-abdominal-surgery patients receiving prehabilitation had significantly lower rates of overall complications (OR 0.61, p=0.005), pulmonary complications (OR 0.41, p<0.001), and cardiac complications (OR 0.46, p=0.044) — so the aggregate evidence leans favorable even though individual high-quality frailty-specific trials (Carli et al.) have not shown benefit.

Crohn Disease — its existing perioperative-optimization section (BSG-guideline-sourced, "reassuring" framing on biologics/steroids) is now cross-linked here for the fuller, messier individual-study evidence picture this chapter presents — a genuine difference in framing/ synthesis-confidence, not a factual contradiction, flagged rather than silently merged.
Ulcerative Colitis — tofacitinib/JAK-inhibitor perioperative VTE data referenced from Crohn Disease's page applies here too.
Diverticulitis — its Special Populations immunocompromised bullet is extended here with quantified figures (40% emergent-op rate vs. 10–25% general, 6.9% mortality) and a practice- changing finding: prophylactic colectomy in immunosuppressed diverticulosis patients is no longer recommended per this chapter's cited review (Biondo), contrary to older teaching.
Total Neoadjuvant Therapy (TNT) — bevacizumab's fistula/healing-risk mention there is corroborated and quantified here (median 9-week hold interval, specific leak case counts).
Ileal Pouch-Anal Anastomosis (IPAA) — obesity's independent effect on pouch-anal leak rate (not just technical reach difficulty) extends that page's existing obesity discussion.
Rectal Cancer — pelvic MRI staging and CT metastatic workup both referenced here as standard preoperative imaging.
Enhanced Recovery After Surgery (ERAS) — companion ASCRS Ch7 covers the recovery pathway/protocol built around this page's risk assessment; their preoperative-hyperglycemia and VTE-prophylaxis content specifically overlaps, cross-linked in both directions rather than restated.
General Postoperative Complications — ASCRS Ch8 covers postoperative complication outcomes (MI/POAF incidence and mortality, VTE risk-stratification scores, postoperative delirium risk factors) that are the outcome side of this page's preoperative cardiac-risk and frailty/cognitive-dysfunction assessment content — cross-linked rather than restated.
Geriatric Considerations in Colorectal Surgery — ASCRS Ch67's dedicated geriatric-surgery chapter extends this page's frailty/CGA/prehabilitation content with additional screening tools, functional-recovery/PROMs, and a rectal-cancer-specific personalized-treatment algorithm.

Open items / gaps

No primary literature yet independently ingested/appraised for any of the many individual studies cited in the Immunosuppressive/Biologics/Chemotherapy section — presented here as the chapter's own (self-acknowledged conflicting) synthesis. This is a strong candidate for a dedicated primary-literature deep-dive if Stephen wants the anastomotic-leak-risk question resolved more rigorously than "the literature disagrees."
Frailty-assessment tools (CGA, Hopkins Frailty Score, mFI, RAI) are presented without a head-to- head comparative source — the chapter references them individually but doesn't rank them.
Prehabilitation's genuinely mixed outcome evidence (strong aggregate signal in meta-analysis, null result in the one frailty-specific RCT) is presented as-is; not a wiki gap so much as an authentically unresolved question in the field.

Colorectal LLM Wiki